Clinical Trials on Hormone-resistant Prostate Cancer in United States

Total 7238 results

Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC

Prostate Cancer | Prostate Neoplasm | Cancer of the Prostate | Prostatic Cancer | Castrate Resistant Prostate Cancer | Cancer of Prostate | Castration Resistant Prostatic Cancer | Castration Resistant Prostatic Neoplasms

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel (DEXTER)

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of California, Irvine
Bristol-Myers Squibb

Completed

Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Hormone-refractory Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Hormone-Resistant Prostate Cancer

United States
Mayo Clinic

Completed

Bicalutamide and Raloxifene in Treating Patients With Metastatic or Hormone-Refractory Prostate Cancer

Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Metastatic Prostate Carcinoma | Prostate Adenocarcinoma | Hormone-Resistant Prostate Cancer

United States
University of California, Davis
Sanofi

Terminated

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Hormone-Resistant Prostate Cancer | Stage IV Prostate Adenocarcinoma

United States
University of Southern California
National Cancer Institute (NCI); AEterna Zentaris

Completed

Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Unknown

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute

Completed

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Washington
National Cancer Institute (NCI)

Withdrawn

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Millennium: The Takeda Oncology Company

Completed

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Completed

Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.

Terminated

Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC

Terminated

Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer

Recurrent Prostate Cancer | Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
OHSU Knight Cancer Institute
Bristol-Myers Squibb; Oregon Health and Science University

Completed

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Clarus Therapeutics

Recruiting

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer

Recurrent Prostate Carcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Hormone-Resistant Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
Massachusetts General Hospital
Bayer

Completed

A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer | Castration-resistant Prostate Cancer Metastatic to Bone

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
Dendreon

Completed

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

Hormone Refractory Prostate Cancer | Castration-resistant Prostate Cancer | Prostate Cancer Metastatic

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects

Metastatic Prostate Cancer | Castration Resistant Prostatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Saracatinib in Treating Patients With Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage IV Prostate Cancer

United States
Stanford University
National Cancer Institute (NCI)

Terminated

NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Metastatic Malignant Neoplasm in the Bone | Hormone-Resistant Prostate Cancer

United States
Northwestern University

Recruiting

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Refractory Prostate Cancer | Castration-Resistant Prostatic Cancer

United States
National Cancer Institute (NCI)

Terminated

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Southern California
National Cancer Institute (NCI); Sanofi

Terminated

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

Diarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer

United States
BAMF Health

Recruiting

Use of SPECT-CT for Comparison of Dosimetry Methods in PSMA-targeted Radioligand Therapy (SPECTacular Study) (SPECTacular)

Metastatic Castration-resistant Prostate Cancer

United States
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Roswell Park Cancer Institute
Dendreon

Completed

Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Janux Therapeutics

Recruiting

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer | Castration Resistant Prostatic Cancer

United States, Australia
National Cancer Institute (NCI)

Completed

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Prostate Adenocarcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of California, San Francisco
Merck Sharp & Dohme LLC; Prostate Cancer Foundation

Recruiting

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Prostate Cancer | Prostate Carcinoma | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer

United States
Sandy Srinivas
Wyeth is now a wholly owned subsidiary of Pfizer; American Society of Clinical... and other collaborators

Terminated

Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
Stanford University

Terminated

Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy

Prostatic Neoplasms | Prostate Cancer | Metastatic Disease | Hormone-refractory Prostate Cancer | Castrate-resistant Prostate Cancer (CRPC) | Androgen-insensitive Prostate Cancer

United States
MANA RBM
Bayer; Tulane University; Barbara Ann Karmanos Cancer Institute; Carolina Urologic...

Terminated

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients (ESCALATE)

Metastatic Castration-resistant Prostate Cancer

United States
Roswell Park Cancer Institute
Active Biotech AB

Completed

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
National Cancer Institute (NCI)

Completed

Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases

Metastatic Malignant Neoplasm in the Bone | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
University of Nebraska
National Cancer Institute (NCI)

Terminated

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate

United States
Jonsson Comprehensive Cancer Center
Novartis; Stand Up To Cancer; Prostate Cancer Foundation

Active, not recruiting

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Metastatic Prostate Carcinoma | Recurrent Prostate Carcinoma | Stage IV Prostate Cancer | Hormone-Resistant Prostate Cancer

United States
Achieve Life Sciences
Teva Pharmaceuticals USA

Terminated

A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Hormone Refractory Prostate Cancer | Castrate-Resistant Prostate Cancer

France, United States, Spain, United Kingdom, Canada

Clinical Trials on Hormone-resistant Prostate Cancer in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations